Engineering Phages as Novel Antimicrobials Targeting Gram-Negative Pathogens – Massachusetts General Hospital’s Bryan Lenneman, Ph.D.
MGH Research Fellow Bryan Lenneman, PhD, is interested in utilizing synthetic biology to develop novel therapeutics against diseases associated with dysbiosis of the human gut microbial community.
Rachel Ende, PhD, Postdoctoral Scholar in the lab of CIMAR’s Dr. Joan Mecsas, studying mechanisms of synergistic antibiotic interactions against Klebsiella pneumoniae in the lungs
Postdoctoral Scholar & first-year IRACDA Fellow in the lab of Levy CIMAR’s Dr. Joan Mecsas, studying mechanisms of synergistic antibiotic interactions against Klebsiella pneumoniae in the lungs
Metabolic Modeling Predicts Unique Drug Targets in Lyme Disease Pathogen B. burgdorferi – TUSM’s Peter Gwynne, PhD
Lyme disease expert Peter Gwynne, PhD, presented on “Metabolic Modeling Predicts Unique Drug Targets in the Lyme Disease Pathogen Borrelia burgdorferi” for the Levy CIMAR's February 2023 Science Seminar. Dr. Gwynne is interested in Borrelia burgdorferi, which causes Lyme disease,
Role of Bacteriophages in the Evolution of Pathogenic Vibrios and Lessons for Phage Therapy
Adv Exp Med Bio.; February 16, 2023
Low frequency of allergy referral for penicillin allergy evaluation in an urban Boston primary care setting
J. Allergy Clin. Immunol. Glob.; February 6, 2023